Longeveron (LGVN)
Longeveron on one page: short interest, daily short volume, fails to deliver, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
73K
Short interest
settlement 2026-10-15
1.0
Days to cover
unchanged vs prior
36.8%
Short share of volume
2026-11-02
5,623
Fails to deliver
settlement 2026-10-13
Tue 3 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in LGVN is 73,177 shares, down 140,600 shares over the last month. Over the last 48 readings it ranged from 73,177 shares (15 October 2026) to 4,553,371 shares (13 March 2026). The latest reading sits at the bottom of that range. At the reported average volume of 73K shares a day that is 1.0 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/lgvn" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 73,177 | -31.5% | 73,334 | 1.00 |
| 2026-09-30 | 106,796 | -50.0% | 286,638 | 1.00 |
| 2026-09-15 | 213,777 | -5.5% | 45,930 | 4.65 |
| 2026-08-31 | 226,295 | -86.7% | 94,901 | 2.38 |
| 2026-08-14 | 1,699,946 | +9.3% | 497,574 | 3.42 |
| 2026-07-31 | 1,554,677 | +1.5% | 213,331 | 7.29 |
| 2026-07-15 | 1,531,232 | -3.9% | 319,008 | 4.80 |
| 2026-06-30 | 1,593,096 | -12.8% | 272,058 | 5.86 |
| 2026-06-15 | 1,826,833 | -15.0% | 196,131 | 9.31 |
| 2026-05-29 | 2,149,154 | -8.2% | 404,893 | 5.31 |
| 2026-05-15 | 2,341,321 | -10.3% | 444,154 | 5.27 |
| 2026-04-30 | 2,609,328 | -10.2% | 530,614 | 4.92 |
| 2026-04-15 | 2,904,113 | +20.7% | 1,072,296 | 2.71 |
| 2026-03-31 | 2,406,104 | -47.2% | 3,391,138 | 1.00 |
| 2026-03-13 | 4,553,371 | +197.5% | 27,825,080 | 1.00 |
| 2026-02-27 | 1,530,744 | +22.9% | 597,234 | 2.56 |
| 2026-02-13 | 1,245,318 | -3.4% | 135,989 | 9.16 |
| 2026-01-30 | 1,288,731 | +17.6% | 204,473 | 6.30 |
| 2026-01-15 | 1,096,021 | +11.9% | 233,972 | 4.68 |
| 2025-12-31 | 979,704 | -26.6% | 372,571 | 2.63 |
| 2025-12-15 | 1,334,145 | -1.0% | 450,850 | 2.96 |
| 2025-11-28 | 1,347,960 | -4.8% | 406,951 | 3.31 |
| 2025-11-14 | 1,415,293 | -17.5% | 446,593 | 3.17 |
| 2025-10-31 | 1,714,583 | +36.3% | 426,599 | 4.02 |
| 2025-10-15 | 1,257,626 | +9.7% | 611,736 | 2.06 |
| 2025-09-30 | 1,146,725 | +5.8% | 316,582 | 3.62 |
| 2025-09-15 | 1,083,940 | -0.9% | 437,813 | 2.48 |
| 2025-08-29 | 1,093,381 | -8.0% | 543,451 | 2.01 |
| 2025-08-15 | 1,187,757 | +132.3% | 3,175,572 | 1.00 |
| 2025-07-31 | 511,329 | -14.1% | 326,650 | 1.57 |
| 2025-07-15 | 595,567 | +58.5% | 1,287,069 | 1.00 |
| 2025-06-30 | 375,851 | -1.1% | 141,314 | 2.66 |
| 2025-06-13 | 379,942 | -17.3% | 158,741 | 2.39 |
| 2025-05-30 | 459,485 | -7.1% | 113,545 | 4.05 |
| 2025-05-15 | 494,589 | -11.2% | 141,407 | 3.50 |
| 2025-04-30 | 557,002 | -16.9% | 103,262 | 5.39 |
| 2025-04-15 | 670,124 | +5.6% | 119,907 | 5.59 |
| 2025-03-31 | 634,445 | -13.9% | 180,099 | 3.52 |
| 2025-03-14 | 736,838 | +31.7% | 437,025 | 1.69 |
| 2025-02-28 | 559,523 | +7.8% | 567,121 | 1.00 |
| 2025-02-14 | 518,880 | -11.5% | 150,185 | 3.45 |
| 2025-01-31 | 586,064 | -21.2% | 167,623 | 3.50 |
| 2025-01-15 | 743,356 | +11.1% | 346,075 | 2.15 |
| 2024-12-31 | 669,305 | -32.0% | 308,583 | 2.17 |
| 2024-12-13 | 984,876 | -0.4% | 330,348 | 2.98 |
| 2024-11-29 | 988,842 | -12.6% | 372,069 | 2.66 |
| 2024-11-15 | 1,131,064 | -11.4% | 469,478 | 2.41 |
| 2024-10-31 | 1,277,023 | +115.0% | 873,299 | 1.46 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of LGVN volume is 36.8%, down 19.1 points over the last five sessions. Over the last 30 readings it ranged from 9.0% (8 October 2026) to 94.9% (29 September 2026). The latest reading is 9.1 points below the 30-session average of 45.9%, on 40K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 15K | 40K | 36.8% | 0 |
| 2026-10-30 | 22K | 38K | 56.9% | 136 |
| 2026-10-29 | 9K | 32K | 26.5% | 0 |
| 2026-10-28 | 14K | 35K | 41.6% | 0 |
| 2026-10-27 | 28K | 59K | 47.4% | 0 |
| 2026-10-26 | 34K | 60K | 56.0% | 2,943 |
| 2026-10-23 | 29K | 37K | 79.8% | 0 |
| 2026-10-22 | 43K | 50K | 86.9% | 0 |
| 2026-10-21 | 34K | 50K | 66.8% | 0 |
| 2026-10-20 | 17K | 28K | 58.0% | 0 |
| 2026-10-19 | 17K | 29K | 57.8% | 0 |
| 2026-10-16 | 14K | 40K | 35.8% | 400 |
| 2026-10-15 | 22K | 86K | 25.7% | 1,737 |
| 2026-10-14 | 22K | 88K | 24.6% | 13,658 |
| 2026-10-13 | 7K | 33K | 21.1% | 366 |
| 2026-10-12 | 6K | 14K | 41.5% | 0 |
| 2026-10-09 | 5K | 38K | 13.6% | 0 |
| 2026-10-08 | 3K | 38K | 9.0% | 0 |
| 2026-10-07 | 7K | 21K | 31.3% | 0 |
| 2026-10-06 | 17K | 49K | 35.3% | 0 |
| 2026-10-05 | 7K | 17K | 40.4% | 0 |
| 2026-10-02 | 7K | 10K | 68.8% | 82 |
| 2026-10-01 | 13K | 46K | 28.7% | 0 |
| 2026-09-30 | 10K | 22K | 44.8% | 0 |
| 2026-09-29 | 37K | 38K | 94.9% | 0 |
| 2026-09-28 | 19K | 78K | 24.0% | 0 |
| 2026-09-25 | 9K | 24K | 36.1% | 0 |
| 2026-09-24 | 58K | 97K | 60.2% | 0 |
| 2026-09-23 | 20K | 29K | 68.8% | 0 |
| 2026-09-22 | 79K | 138K | 57.8% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 13 October 2026, the fails-to-deliver balance in LGVN is 5,623 shares, up 4,397 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (16 September 2026) to 118,422 shares (20 August 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-13 | 5,623 | $2.45 | $14K |
| 2026-10-08 | 1,226 | $2.44 | $3K |
| 2026-10-02 | 379 | $2.59 | $982 |
| 2026-09-30 | 3,691 | $2.72 | $10K |
| 2026-09-25 | 2 | $2.91 | $6 |
| 2026-09-24 | 416 | $2.60 | $1K |
| 2026-09-23 | 21 | $2.72 | $57 |
| 2026-09-22 | 11,464 | $2.45 | $28K |
| 2026-09-21 | 81 | $2.49 | $202 |
| 2026-09-18 | 9,145 | $2.71 | $25K |
| 2026-09-17 | 19,970 | $6.68 | $133K |
| 2026-09-16 | 1 | $6.86 | $7 |
| 2026-09-15 | 1,548 | $6.92 | $11K |
| 2026-09-14 | 6,293 | $7.33 | $46K |
| 2026-09-11 | 4,995 | $6.64 | $33K |
| 2026-09-09 | 1,448 | $6.65 | $10K |
| 2026-09-08 | 1,839 | $6.81 | $13K |
| 2026-09-04 | 994 | $6.58 | $7K |
| 2026-09-03 | 1,004 | $6.78 | $7K |
| 2026-09-02 | 1,029 | $6.75 | $7K |
| 2026-09-01 | 2,269 | $6.90 | $16K |
| 2026-08-31 | 6,581 | $6.72 | $44K |
| 2026-08-28 | 10,298 | $6.80 | $70K |
| 2026-08-25 | 196 | $0.84 | $165 |
| 2026-08-20 | 118,422 | $0.82 | $97K |
| 2026-08-17 | 1,619 | $0.74 | $1K |
| 2026-08-14 | 246 | $0.70 | $172 |
| 2026-08-13 | 4,602 | $0.75 | $3K |
| 2026-08-12 | 11,050 | $0.69 | $8K |
| 2026-08-10 | 27,469 | $0.77 | $21K |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for LGVN in the last 90 days. The most recent filings are listed below. Latest filing: Willard Stephen H (Chief Executive Officer) on 2026-10-01.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Willard Stephen H | Chief Executive Officer | Tax withholding | 2K | $2.59 | $5K | 75K |
| 2026-10-01 | Lehr Paul T | General Counsel, Secretary | Tax withholding | 2K | $2.59 | $6K | 84K |
| 2026-10-01 | Jhaveri Nirav S. | Chief Financial Officer | Tax withholding | 742 | $2.59 | $2K | 29K |
| 2026-10-01 | Blass Devin | CTO & SVP of CMC | Tax withholding | 3K | $2.59 | $7K | 69K |
| 2026-10-01 | Agafonova Nataliya | Chief Medical Officer | Tax withholding | 3K | $2.59 | $8K | 69K |
| 2026-08-19 | Soffer Rock | Director | Grant | 36K | $0.00 | $0 | 262K |
| 2026-08-19 | Paletta George A. Jr. | Director | Grant | 36K | $0.00 | $0 | 70K |
| 2026-08-19 | Ungaro Ursula | Director | Grant | 36K | $0.00 | $0 | 77K |
| 2026-08-19 | Lehr Paul T | General Counsel, Secretary | Grant | 286K | $0.00 | $0 | 861K |
| 2026-08-19 | Hare Joshua | Chief Scientific Officer | Grant | 286K | $0.00 | $0 | 1.6M |
| 2026-08-19 | Hajjar Roger Joseph | Director | Grant | 36K | $0.00 | $0 | 69K |
| 2026-08-19 | Desai Arjun JJ | Director | Grant | 36K | $0.00 | $0 | 36K |
| 2026-08-19 | Cann Leah Rush | Director | Grant | 36K | $0.00 | $0 | 36K |
| 2026-08-19 | Blass Devin | CTO & SVP of CMC | Grant | 286K | $0.00 | $0 | 712K |
| 2026-08-19 | Ascheim Deborah | Director | Grant | 36K | $0.00 | $0 | 36K |
| 2026-08-19 | Agafonova Nataliya | Chief Medical Officer | Grant | 286K | $0.00 | $0 | 717K |
| 2026-08-17 | Jhaveri Nirav S. | Chief Financial Officer | Grant | 300K | $0.00 | $0 | 300K |
| 2026-07-06 | Hare Joshua | Chief Scientific Officer | Grant | 600K | $0.00 | $0 | 1.3M |
| 2026-07-01 | Willard Stephen H | Chief Executive Officer | Tax withholding | 18K | $0.73 | $13K | 772K |
| 2026-07-01 | Locklear Lisa | Chief Financial Officer | Tax withholding | 23K | $0.73 | $16K | 443K |
| 2026-07-01 | Lehr Paul T | General Counsel, Secretary | Tax withholding | 13K | $0.73 | $10K | 575K |
| 2026-07-01 | Blass Devin | CTO & SVP of CMC | Tax withholding | 16K | $0.73 | $12K | 426K |
| 2026-07-01 | Agafonova Nataliya | Chief Medical Officer | Tax withholding | 23K | $0.73 | $16K | 431K |
| 2026-05-01 | Willard Stephen H | Chief Executive Officer | Grant | 500K | $0.00 | $0 | 790K |
| 2026-05-01 | Locklear Lisa | Chief Financial Officer | Grant | 250K | $0.00 | $0 | 466K |
| 2026-05-01 | Lehr Paul T | General Counsel, Secretary | Grant | 250K | $0.00 | $0 | 589K |
| 2026-05-01 | Blass Devin | CTO & SVP of CMC | Grant | 250K | $0.00 | $0 | 442K |
| 2026-05-01 | Agafonova Nataliya | Chief Medical Officer | Grant | 250K | $0.00 | $0 | 453K |
| 2026-04-01 | Willard Stephen H | Chief Executive Officer | Tax withholding | 5K | $1.12 | $5K | 290K |
| 2026-04-01 | Locklear Lisa | Chief Financial Officer | Tax withholding | 13K | $1.12 | $15K | 216K |
| 2026-04-01 | Lehr Paul T | General Counsel, Secretary | Tax withholding | 6K | $1.12 | $6K | 339K |
| 2026-04-01 | Blass Devin | CTO & SVP of CMC | Tax withholding | 9K | $1.12 | $10K | 192K |
| 2026-04-01 | Agafonova Nataliya | Chief Medical Officer | Tax withholding | 13K | $1.12 | $15K | 203K |
| 2026-03-02 | Willard Stephen H | Chief Executive Officer | Grant | 200K | $0.00 | $0 | 294K |
| 2026-03-02 | Willard Stephen H | Chief Executive Officer | Tax withholding | 106K | $0.55 | $58K | 94K |
| 2026-03-02 | Willard Stephen H | Chief Executive Officer | Grant | 200K | $0.00 | $0 | 200K |
| 2026-01-02 | Powell James Nathaniel | Chief Executive Officer | Tax withholding | 2K | $0.59 | $1K | 126K |
| 2026-01-02 | Locklear Lisa | Chief Financial Officer | Tax withholding | 10K | $0.59 | $6K | 229K |
| 2026-01-02 | Lehr Paul T | General Counsel, Secretary | Tax withholding | 7K | $0.59 | $4K | 344K |
| 2026-01-02 | Blass Devin | CTO & SVP of CMC | Tax withholding | 11K | $0.59 | $6K | 200K |
| 2026-01-02 | Agafonova Nataliya | Chief Medical Officer | Tax withholding | 10K | $0.59 | $6K | 217K |
| 2025-10-01 | Powell James Nathaniel | Chief Executive Officer | Tax withholding | 2K | $0.74 | $2K | 128K |
| 2025-10-01 | Locklear Lisa | Chief Financial Officer | Tax withholding | 12K | $0.74 | $9K | 239K |
| 2025-10-01 | Lehr Paul T | General Counsel, Secretary | Tax withholding | 5K | $0.74 | $4K | 351K |
| 2025-10-01 | Blass Devin | CTO & SVP of CMC | Tax withholding | 8K | $0.74 | $6K | 211K |
| 2025-10-01 | Agafonova Nataliya | Chief Medical Officer | Tax withholding | 12K | $0.74 | $9K | 227K |
| 2025-10-01 | Paletta George A. Jr. | Director | Grant | 34K | $0.00 | $0 | 34K |
| 2025-09-04 | Powell James Nathaniel | Chief Executive Officer | Grant | 50K | $0.00 | $0 | 130K |
| 2025-08-11 | Baluch Khoso | Director | Buy | 12K | price not stated in the filing | not stated | 53K |
| 2025-08-11 | Locklear Lisa | Chief Financial Officer | Buy | 12K | price not stated in the filing | not stated | 251K |
| 2025-07-15 | Soffer Rock | Director | Grant | 17K | $0.00 | $0 | 226K |
| 2025-07-15 | Motwani Neha J. | Director | Grant | 17K | $0.00 | $0 | 33K |
| 2025-07-15 | Ungaro Ursula | Director | Grant | 17K | $0.00 | $0 | 41K |
| 2025-07-15 | Locklear Lisa | Chief Financial Officer | Grant | 102K | $0.00 | $0 | 239K |
| 2025-07-15 | Lehr Paul T | General Counsel, Secretary | Grant | 102K | $0.00 | $0 | 356K |
| 2025-07-15 | Kender Richard N | Director | Grant | 17K | $0.00 | $0 | 33K |
| 2025-07-15 | Hashad Mohamed Wa'el Ahmed | Chief Executive Officer | Grant | 180K | $0.00 | $0 | 421K |
| 2025-07-15 | Hajjar Roger Joseph | Director | Grant | 17K | $0.00 | $0 | 33K |
| 2025-07-15 | Blass Devin | CTO & SVP of CMC | Grant | 102K | $0.00 | $0 | 218K |
| 2025-07-15 | Baluch Khoso | Director | Grant | 17K | $0.00 | $0 | 41K |
| 2025-07-15 | Agafonova Nataliya | Chief Medical Officer | Grant | 102K | $0.00 | $0 | 239K |
| 2025-07-01 | Locklear Lisa | Chief Financial Officer | Tax withholding | 7K | $1.28 | $10K | 137K |
| 2025-07-01 | Lehr Paul T | General Counsel, Secretary | Tax withholding | 2K | $1.28 | $2K | 254K |
| 2025-07-01 | Hashad Mohamed Wa'el Ahmed | Chief Executive Officer | Tax withholding | 13K | $1.28 | $17K | 241K |
| 2025-07-01 | Blass Devin | CTO & SVP of CMC | Tax withholding | 5K | $1.28 | $6K | 116K |
| 2025-07-01 | Agafonova Nataliya | Chief Medical Officer | Tax withholding | 7K | $1.28 | $10K | 137K |
| 2025-06-23 | Lehr Paul T | General Counsel, Secretary | Tax withholding | 64K | $1.15 | $74K | 256K |
| 2025-06-23 | Lehr Paul T | General Counsel, Secretary | Grant | 163K | $0.00 | $0 | 320K |
| 2025-05-30 | Soffer Rock | Director | Sell | 11K | $1.25 | $14K | 209K |
| 2025-05-29 | Soffer Rock | Director | Sell | 10K | $1.30 | $13K | 220K |
| 2025-05-22 | Soffer Rock | Director | Sell | 2K | $1.32 | $3K | 230K |
| 2025-05-16 | Hare Joshua | Chief Scientific Officer | Sell | 5K | $1.40 | $7K | 722K |
| 2025-04-01 | Lehr Paul T | General Counsel, Secretary | Tax withholding | 2K | $1.50 | $2K | 157K |
| 2025-04-01 | Hashad Mohamed Wa'el Ahmed | Chief Executive Officer | Tax withholding | 13K | $1.50 | $20K | 254K |
| 2025-04-01 | Locklear Lisa | Chief Financial Officer | Tax withholding | 8K | $1.50 | $11K | 145K |
| 2025-04-01 | Agafonova Nataliya | Chief Medical Officer | Tax withholding | 8K | $1.50 | $11K | 144K |
| 2025-01-02 | Lehr Paul T | General Counsel, Secretary | Tax withholding | 1K | $1.79 | $2K | 158K |
| 2025-01-02 | Locklear Lisa | Chief Financial Officer | Tax withholding | 6K | $1.79 | $11K | 152K |
| 2025-01-02 | Hashad Mohamed Wa'el Ahmed | Chief Executive Officer | Tax withholding | 11K | $1.79 | $19K | 267K |
| 2025-01-02 | Agafonova Nataliya | Chief Medical Officer | Tax withholding | 6K | $1.79 | $11K | 152K |
| 2024-12-02 | Baluch Khoso | Director | Sell | 1K | $2.07 | $3K | 24K |
| 2024-10-01 | Hashad Mohamed Wa'el Ahmed | Chief Executive Officer | Tax withholding | 13K | $1.88 | $25K | 278K |
| 2024-10-01 | Lehr Paul T | General Counsel, Secretary | Tax withholding | 990 | $1.88 | $2K | 160K |
| 2024-10-01 | Agafonova Nataliya | Chief Medical Officer | Tax withholding | 5K | $1.88 | $10K | 158K |
| 2024-10-01 | Locklear Lisa | Chief Financial Officer | Tax withholding | 5K | $1.88 | $10K | 158K |
| 2024-08-15 | Hare Neil E | Director | Grant | 24K | $0.00 | $0 | 29K |
| 2024-08-15 | Soffer Rock | Director | Grant | 24K | $0.00 | $0 | 232K |
| 2024-08-15 | Ungaro Ursula | Director | Grant | 24K | $0.00 | $0 | 24K |
| 2024-08-15 | Baluch Khoso | Director | Grant | 24K | $0.00 | $0 | 38K |
| 2024-08-15 | Hare Joshua | Chief Scientific Officer | Grant | 94K | $0.00 | $0 | 727K |
| 2024-08-15 | Lehr Paul T | General Counsel, Secretary | Grant | 178K | $0.00 | $0 | 320K |
| 2024-08-15 | Lehr Paul T | General Counsel, Secretary | Tax withholding | 32K | $2.46 | $78K | 289K |
| 2024-08-15 | Hashad Mohamed Wa'el Ahmed | Chief Executive Officer | Tax withholding | 39K | $2.46 | $97K | 90K |
| 2024-08-15 | Hashad Mohamed Wa'el Ahmed | Chief Executive Officer | Grant | 311K | $0.00 | $0 | 331K |
| 2024-08-15 | Locklear Lisa | Chief Financial Officer | Grant | 175K | $0.00 | $0 | 178K |
| 2024-08-15 | Locklear Lisa | Chief Financial Officer | Tax withholding | 14K | $2.46 | $35K | 164K |
| 2024-08-15 | Agafonova Nataliya | Chief Medical Officer | Grant | 176K | $0.00 | $0 | 178K |
| 2024-08-15 | Agafonova Nataliya | Chief Medical Officer | Tax withholding | 14K | $2.46 | $35K | 163K |
| 2024-07-02 | Motwani Neha J. | Director | Grant | 16K | $1.68 | $27K | 16K |
| 2024-07-02 | Hajjar Roger Joseph | Director | Grant | 16K | $1.68 | $27K | 16K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON14 holders report 5% or more of LGVN in their latest filing, all on Schedule 13G (passive). The largest reported stake is Mitchell P. Kopin at 9.0% of the class (2,941,180 shares), filed 2026-08-13 for an event on 2026-06-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-09-10 | 13G | Logos Global Management LPinvestment adviser, partnership | 192K | 6.3% | 2026-09-02 |
| 2026-09-10 | 13G | Logos Global Management GP LLCparent holding company, other entity | 192K | 6.3% | 2026-09-02 |
| 2026-09-10 | 13G | Logos Opportunities Fund V LPpartnership | 192K | 6.3% | 2026-09-02 |
| 2026-09-10 | 13G | Logos Opportunities V GP LLCparent holding company, other entity | 192K | 6.3% | 2026-09-02 |
| 2026-09-10 | 13G | Arsani Williamparent holding company, individual | 192K | 6.3% | 2026-09-02 |
| 2026-09-10 | 13G | Graham Walmsleyparent holding company, individual | 192K | 6.3% | 2026-09-02 |
| 2026-08-13 | 13G/Ano. 1 | Mitchell P. Kopinparent holding company, individual | 2.9M | 9.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 1 | Daniel B. Asherparent holding company, individual | 2.9M | 9.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 1 | Intracoastal Capital LLCother entity | 2.9M | 9.0% | 2026-06-30 |
| 2026-08-10 | 13G | Integrated Core Strategies (US) LLCother entity | 1.6M | 5.2% | 2026-08-04 |
| 2026-08-10 | 13G | Millennium Management LLCother entity | 1.6M | 5.2% | 2026-08-04 |
| 2026-08-10 | 13G | Millennium Group Management LLCother entity | 1.6M | 5.2% | 2026-08-04 |
| 2026-08-10 | 13G | Israel A. Englanderindividual | 1.6M | 5.2% | 2026-08-04 |
| 2026-05-15 | 13G | JANUS HENDERSON GROUP PLCparent holding company | 1.3M | 5.9% | 2026-03-31 |
| 2026-02-10 | 13G/Ano. 1 | Lincoln Alternative Strategies LLCother entity | 0 | 0.0% | 2025-08-13 |
13F holders
Tracked managers holding LGVN at their latest 13F. JSON2 of the 30 tracked managers held LGVN at their latest 13F, $966K in total at quarter-end prices. Millennium Management is the largest at $952K (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 2 added shares and 0 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Millennium Management | 2026-06-30 | 1.4M | $952K | 0.00% | +907K |
| Renaissance Technologies | 2026-06-30 | 20K | $14K | 0.00% | new |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Longeveron in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Longeveron (LGVN), SEC CIK 1721484, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-13.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-09-10.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-12.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-01.JSON and CSV
- Company record
- EDGAR filing index for CIK 1721484Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of LGVN is sold short?
73,177 shares were held short at the 2026-10-15 settlement, 1.0 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is LGVN's daily short volume?
On 2026-11-02, 14,683 of the 39,853 LGVN shares reported to FINRA were sold short, 36.8% of the day's reported volume. Short volume is a flow for one day, not a position.
Does LGVN have fails to deliver?
The SEC's latest file shows 5,623 LGVN shares failed to deliver at settlement 2026-10-13. Fails are reported per settlement date and published twice a month with a lag.
Are LGVN insiders buying or selling?
No open-market insider trades were reported for LGVN in the last 90 days. The most recent filings are listed below. Latest filing: Willard Stephen H (Chief Executive Officer) on 2026-10-01.
Who owns 5% or more of LGVN?
14 holders report 5% or more of LGVN in their latest filing, all on Schedule 13G (passive). The largest reported stake is Mitchell P. Kopin at 9.0% of the class (2,941,180 shares), filed 2026-08-13 for an event on 2026-06-30.
Which tracked 13F managers own LGVN?
2 of the 30 tracked 13F managers held LGVN shares at their latest filing, $966K in all. The largest: Izzy Englander's Millennium Management (1.4M shares, $952K), Renaissance Technologies (20K shares, $14K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.